[Form 4] INSMED Inc Insider Trading Activity
Rhea-AI Filing Summary
Insmed Inc. (INSM) Chair and CEO William Lewis reported a series of option exercises and related stock sales on January 12, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. He exercised stock options for 6,259 shares of common stock at $30.46 per share and 4,440 shares at $17.16 per share, converting these into common shares.
On the same date he sold multiple blocks of Insmed common stock, including 3,974 shares at a weighted average price of $167.73 and 7,176 shares at $168.63, with additional smaller sales up to $174.86 per share. After these transactions, he directly owned 306,891 shares of common stock and indirectly held 233,924 shares through the Katie Procter Dynasty Trust and 50,500 shares through the William Lewis Family Legacy Trust. He also held 81,368 and 57,720 stock options remaining from the exercised grants.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 6,259 | $0.00 | -- |
| Exercise | Stock Option (right to buy) | 4,440 | $0.00 | -- |
| Exercise | Common Stock | 6,259 | $30.46 | $191K |
| Exercise | Common Stock | 4,440 | $17.16 | $76K |
| Sale | Common Stock | 3,974 | $167.73 | $667K |
| Sale | Common Stock | 7,176 | $168.63 | $1.21M |
| Sale | Common Stock | 6,996 | $169.57 | $1.19M |
| Sale | Common Stock | 160 | $170.24 | $27K |
| Sale | Common Stock | 297 | $171.31 | $51K |
| Sale | Common Stock | 297 | $172.36 | $51K |
| Sale | Common Stock | 315 | $174.86 | $55K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. This is the weighted average sales price representing 3,974 shares sold at prices ranging from $167.11 to $168.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 7,176 shares sold at prices ranging from $168.11 to $169.10 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 6,996 shares sold at prices ranging from $169.11 to $170.08 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 160 shares sold at prices ranging from $170.12 to $170.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 297 shares sold at prices ranging from $171.21 to $171.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. This is the weighted average sales price representing 297 shares sold at prices ranging from $172.26 to $172.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
